Published in Vaccine on September 21, 2011
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One (2013) 1.23
Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol (2013) 1.11
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One (2012) 1.01
Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One (2013) 0.92
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial. Hum Vaccin Immunother (2013) 0.87
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis (2012) 0.87
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine (2014) 0.81
Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Clin Vaccine Immunol (2012) 0.81
Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol (2015) 0.80
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype. J Virol (2015) 0.79
The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies. Sci Rep (2016) 0.77
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. Vaccine (2014) 0.77
Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines. J Virol (2015) 0.75
Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. PLoS One (2015) 0.75
Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections. J Infect Dis (2015) 0.75
Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot study. BMC Res Notes (2014) 0.75
Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types. Oncotarget (2017) 0.75
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Classification of papillomaviruses. Virology (2004) 14.16
A review of human carcinogens--Part B: biological agents. Lancet Oncol (2009) 13.85
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology (2010) 7.24
Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis (2008) 5.69
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus. J Virol (2008) 2.37
Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol (2007) 2.25
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst (2009) 1.95
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine (2010) 1.94
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine (2008) 1.75
Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis (2009) 1.70
Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin (2007) 1.61
Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer (2007) 1.22
Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health (2009) 1.15
Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol (2010) 1.14
Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol (2010) 1.06
Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol (2010) 1.03
Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. Clin Vaccine Immunol (2011) 1.03
Public health. High hopes and dilemmas for a cervical cancer vaccine. Science (2005) 0.88
Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol (2008) 0.85
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35
Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev (2006) 2.48
The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood (2002) 1.66
Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr (2007) 1.64
Who is being tested by the English National Chlamydia Screening Programme? A comparison with national probability survey data. Sex Transm Infect (2011) 1.62
The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles. Virology (2005) 1.40
Human papillomavirus genotype detection and viral load in paired genital and urine samples from both females and males. J Med Virol (2011) 1.39
Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol (2013) 1.29
A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One (2013) 1.23
Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunisation. Vaccine (2012) 1.21
Testing for sexually transmitted infections in a population-based sexual health survey: development of an acceptable ethical approach. J Med Ethics (2012) 1.21
Genital warts and cost of care in England. Sex Transm Infect (2011) 1.19
Overcoming the barriers to chlamydia screening in general practice--a qualitative study. Fam Pract (2010) 1.18
Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother (2008) 1.10
Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis (2011) 1.07
Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect (2012) 1.07
Estimation of the rate of pelvic inflammatory disease diagnoses: trends in England, 2000-2008. Sex Transm Dis (2011) 1.06
DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer (2009) 1.04
Repeat genital Chlamydia trachomatis testing rates in young adults in England, 2010. Sex Transm Infect (2012) 1.03
Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One (2012) 1.01
Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection. Stat Med (2012) 1.01
Purified, proteolytically mature HIV type 1 SOSIP gp140 envelope trimers. AIDS Res Hum Retroviruses (2007) 0.98
Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis (2013) 0.96
Estimating progression rates for human papillomavirus infection from epidemiological data. Med Decis Making (2009) 0.96
Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother (2011) 0.93
Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex. Virology (2006) 0.90
Developing role of HPV in cervical cancer prevention. BMJ (2013) 0.87
Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Int J Epidemiol (2015) 0.85
C. trachomatis Pgp3 antibody prevalence in young women in England, 1993-2010. PLoS One (2013) 0.84
Long-term survivors in Nairobi: complete HIV-1 RNA sequences and immunogenetic associations. J Infect Dis (2004) 0.83
Failure to diagnose recent hepatitis C virus infections in London injecting drug users. J Med Virol (2004) 0.82
Exploring reasons for variation in urinary catheterisation prevalence in care homes: a qualitative study. Age Ageing (2008) 0.82
Modelling borderline and mild dysplasia associated with HPV 6 and 11 infection. Vaccine (2011) 0.81
Human papillomavirus antibody reference reagents for use in postvaccination surveillance serology. Clin Vaccine Immunol (2012) 0.81
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer. Int J Cancer (2011) 0.79
The 'Red Queen' dilemma--running to stay in the same place: reflections on the evolutionary vector of HBV in humans. Antivir Ther (2013) 0.78
Human papillomavirus vaccine coverage. Lancet (2010) 0.78
Promoting chlamydia screening with posters and leaflets in general practice--a qualitative study. BMC Public Health (2009) 0.78
Opportunistic or population register based programmes for chlamydia screening? BMJ (2012) 0.78
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis (2016) 0.78
Danish health register study: a randomised trial with findings about the implementation of chlamydia screening, but not about its benefits. Sex Transm Infect (2011) 0.75
Author's reply to: Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2011) 0.75
A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia. J Med Virol (2006) 0.75